
Opinion|Videos|January 17, 2024
Emergent Data from the ALPINE Trial Investigating Zanubrutinib in the Treatment of Relapsed/Refractory CLL
Author(s)Mazyar Shadman, MD, MPH
Dr Shadman provides an overview of zanubrutinib efficacy and safety data for relapsed/refractory CLL from the Phase 2 ALPINE trial.
Episodes in this series







































